末梢血単核球移植による血管再生治療(再生医療とアフェレシス)

概要

論文の詳細を見る
The discovery of bone marrow-derived endothelial progenitors in the peripheral blood has promoted intensive studies on the potential of cell therapy for various human diseases. Accumulating evidence has suggested that the implantation of bone marrow mononuclear cells effectively promotes neovascularization in ischemic tissues. It has also been reported that the implanted cells are not only incorporated into the newly formed vessels, but also secrete angiogenic factors. However, the mechanism by which cell therapy improves tissue ischemia remains obscure. We enrolled 29 no-option patients with critical limb ischemia and treated ischemic limbs by the implantation of peripheral mononuclear cells. Cell therapy using peripheral mononuclear cells was very effective for the treatment of limb ischemia, and its efficacy was associated with increases in the plasma levels of angiogenic factors; in particular, interleukin-1β(IL-1β). We then examined an experimental model of limb ischemia using IL-1β-deficient mice and found that implanted cells do not secrete angiogenic factors sufficient for neovascularization, but instead stimulate muscle cells to produce angiogenic factors, thereby promoting neovascularization in ischemic tissues. Further studies will allow us to develop more effective treatments for ischemic vascular disease.
日本アフェレシス学会の論文
2006-10-31